Olink Holding (OLK) Receives a Hold from Goldman Sachs

Goldman Sachs analyst Matthew Sykes maintained a Hold rating on Olink Holding (OLKResearch Report) today and set a price target of $16.00. The company’s shares closed last Thursday at $16.56.

According to, Sykes ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.5% and a 39.4% success rate. Sykes covers the Healthcare sector, focusing on stocks such as Singular Genomics Systems, Nautilus Biotechnolgy, and Mettler-Toledo.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Olink Holding with a $17.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Olink Holding AB has a proprietary and patented Proximity Extension Assay technology, which enables researchers to use one platform for discovery to clinical trials to diagnostic applications utilizing the established infrastructure of labs and installed instrumentation. It has two segments including Kit and Services. It derives revenues from Sweden, the Americas, China, and other regions.

Read More on OLK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More